Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJM112 in moderate to severe asthma
NCT03299686Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2017
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of CJM112 in asthma, sponsored by Novartis. Started Nov 2017; status: completed.
02
Drugs
CJM112
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03299686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03299686.